GlassScriptPhysician profile
Alex Vaclavik
NPI 1487800272
$1,361.84
in general payments reported to CMS, 2019-2025
19 companies · $58.12 in 2025
The $58.12 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2021: $85.39 · 2022: $455 · 2023: $262 · 2024: $354 · 2025: $58.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $482.96 | 2022-2024 | Wegovy |
| Abbvie INC. | $341.88 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Myriad Women'S Health, INC. | $70.86 | 2023 | Myrisk |
| Mayne Pharma Commercial LLC | $60.11 | 2022-2025 | |
| Agile Therapeutics, INC. | $56.59 | 2021-2023 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $53.51 | 2021-2025 | |
| Hologic Sales and Service, LLC | $45.99 | 2024 | Acessa Provu System |
| Therapeuticsmd, INC. | $42.90 | 2019-2021 | |
| Boston Scientific Corporation | $29.02 | 2023 | Upsylon |
| Astellas Pharma US INC | $22.75 | 2024 | Veozah |
| Coopersurgical, INC. | $19.72 | 2024 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $18.81 | 2019 | |
| Pfizer INC. | $18.50 | 2023 | |
| Sumitomo Pharma America, INC. | $18.47 | 2023 | Myfembree |
| Abbott Laboratories | $18.41 | 2023 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mycovia Pharmaceuticals, INC. | $18.00 | 2023 | Vivjoa |
| Exeltis, USA INC. | $15.28 | 2022 | |
| Renovia INC | $14.07 | 2021 | |
| Lilly USA, LLC | $14.01 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Vaclavik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.